Modeling global transfusion medicine education

Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron

“…We need some new mRNA cassettes and put them in if one needs to produce a new vaccine. Hence creating a new plant locally in Africa is the best option for such a new vaccine production locally to the benefit of all, a real breakthrough in countries with poor infrastructure where most needed [11] .…”

“…One promising therapeutic option is based on the administration of some polyclonal antibodies hyper concentrate, easily obtainable from online immunoadsorption from either convalescing donor volunteers or other sources, including from doubled dose vaccinated donors having optimal protection against Cov2 strains. The online processing of circulating plasma should be in the range of 200 to 1200 mL [11] , [12] . The mobile therapeutic apheresis process may partially remove the neutralising CoV2 antibodies as a new therapeutic product and be used in-patient suffering from autoimmune diseases immunocompromised and for the poor or non-responders to vaccines [11] , [13] , [14] .…”

“…The online processing of circulating plasma should be in the range of 200 to 1200 mL [11] , [12] . The mobile therapeutic apheresis process may partially remove the neutralising CoV2 antibodies as a new therapeutic product and be used in-patient suffering from autoimmune diseases immunocompromised and for the poor or non-responders to vaccines [11] , [13] , [14] . Moreover, such plasma donations could be pooled under GMP regulatory conditions for standardisation of the antibodies contents and after immunoadsorption resuspended in the cryosupernatant co-administrated during transfusion, providing not only the standardised dose of neutralising antibody free from the potentially toxic elements of the source products and resuspended, in SD plasma or cryosupernatant to compensate for the content of Albumin and Antithrombin that are low in severe cases on COVID patients.…”

“…It could also be used in poor responders and non-responders to any vaccines, where no remedial action exists, except newer drug therapy with an enormous cost. Moreover, such a product could be obtained on a large scale even from cadaveric serum under the auspices of some interested manufacturers under GMP regulatory conditions [11] , [16] .…”

“…The use of antiviral and anti-inflammatory drug therapy is considered amongst the broad intervention armatures to stop the progression of COVID infection. But often with partial success, where like in all innovative interventions, the risks benefit stratification had to be taken into consideration for their usages for all ages, and where artificial intelligence in big data and pattern analysis were instrumental in the identification of the best products and the best practices [11] .…”